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Abstract: There is a scarcity of published research describing the impact of a pharmacist on the post-
take ward round (PTWR) in addition to ward-based pharmacy services. The aim of this paper was 
to evaluate the impact of clinical pharmacists’ participation on the PTWR on the risk assessment 
scores of medication-related recommendations with and without a pharmacist. This includes 
medication-related recommendations occurring on the PTWR and those recommendations made by 
the ward-based pharmacist on the inpatient ward. A pre–post intervention study was undertaken 
that compared the impact of adding a pharmacist to the PTWR compared with ward-based 
pharmacist services alone. A panel reviewed the risk of not acting on medication recommendations 
that was made on the PTWR and those recorded by the ward-based pharmacist. The relationship 
between the risk scores and the number and proportion of recommendations that led to action were 
compared between study groups. There were more medication-related recommendations on the 
PTWR in the intervention group when a pharmacist was present. Proportionately fewer were in the 
’very high and extreme’ risk category. Although there was no difference in the number of ward 
pharmacist recommendations between groups, there was a significantly higher proportion of ward 
pharmacist recommendations in the “very high and extreme” category in those patients who had 
been seen on a PTWR attended by a pharmacist than when a pharmacist was not present. There 
were a greater proportion of “low and medium” risk actionable medication recommendations 
actioned on the PTWR in the intervention group; and no difference in the risk scores in ward 
pharmacist recommendations actioned between groups. Overall, the proportion of 
recommendations that were actioned was higher for those made on the PTWR compared with the 
ward. The addition of a pharmacist to the PTWR resulted in an increase in low, medium, and high 
risk recommendations on the PTWR, more very high and extreme risk recommendations made by 
the ward-based pharmacist, plus an increased number of recommendations being actioned during 
the patients’ admission. 
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1. Introduction 
Drug-related problems (DRP), which are associated with increased morbidity, mortality, and 
healthcare costs, must be identified and addressed [1]. This is a current global health challenge [2]. 
There are numerous ways in which hospitals aim to reduce DRPs and optimize medication use for 
patients, one of which are clinical pharmacists. The literature provides strong evidence for the impact 
of clinical pharmacists, who work with medical officers to optimize the use of medicines and improve 
the safety and appropriateness of prescribing [3]; they assist with the identification, resolution, and 
prevention of DRPs reducing morbidity, hospital mortality rates, and medicine-related incidents in 
the majority of cases [4] . In Australia, this medication review by a pharmacist usually occurs on the 
inpatient ward and, for the purposes of this paper, are termed “ward-based pharmacy services”[5]. 
An ideal opportunity for identification and resolution of DRPs is on the ward round where the 
medical officers and pharmacists have been shown to discuss and optimize patient’s medication 
management [6]. This paper focuses on a specific type of ward round, called the post-take ward round 
(PTWR) where the admitted patient is first presented to the treating consultant medical officer and 
an initial inpatient management plan is formulated [5,7]. It has been demonstrated that clinical 
pharmacist attendance on the PTWR leads to an increase in the number of medication-related 
discussions with more appropriate medications prescribed at the time of discharge [5,7]. 
The Society of Hospital Pharmacists of Australia (SHPA) recommends that a risk assessment 
should be done for clinical interventions regarding medications in order to assess the potential 
significance of their impact and assist prioritization of resources [3]. Further to what we know about 
pharmacists working on PTWRs, this paper investigates the impact of a PTWR pharmacist on the 
level of risk assigned to all medication-related recommendations both on the PTWR and 
subsequently on the ward: This has not been previously reported. Risk scoring often includes a 
description of the adverse consequences and their likelihood if there is no intervention [8].  
2. Aim 
The aim of this study is to evaluate the impact of clinical pharmacist participation on the PTWR 
on the risk assessment and enactment of medication-related recommendations discussed on the 
PTWR and subsequent recommendations made by the ward-based pharmacist. 
3. Ethics Approval 
Ethics approval was obtained from the Hospital and University Human Research Ethics 
Committees (HREC/13/QRBW/443;2014000705). Verbal consent was obtained and recorded for all 
patients and written consent was obtained from all pharmacists and medical officers (MOs) prior to 
the period of observation. Consent could be withdrawn at any time. 
4. Methods 
4.1. Study Design: 
The study occurred in the Internal Medicine Department at a 929-bed quaternary and tertiary 
referral teaching hospital in Brisbane, Australia. In brief, in the initial six-week phase (comparator 
group: April to June 2014), pharmacist input occurred on the ward to which the patient was 
transferred after the PTWR with no pharmacist present on the PTWR. By contrast, in the second six-
week phase (intervention group: August to October 2014), one of four senior clinical pharmacists 
were present on the PTWR and interacted with medical staff: This was in addition to ward-based 
pharmacy input. One experienced pharmacist observed PTWRs in both study phases but did not 
participate in any prescribing decisions unless there was a need to intervene to prevent or highlight 
a potential adverse event that had so far not been recognized and that may have caused immediate 
harm. The presence of the PTWR in the intervention group was in addition to the usual ward-based 
pharmacy service, which was present in both groups. 
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During both study phases, all observed medication-related communication on the PTWR was 
recorded. Retrospectively, all medication-related recommendations made by the ward pharmacist 
and recorded on the Medication Action Plan (MAP) were recorded. 
The methods for the comparator and intervention observation study are described in further detail 
in an earlier publication by Bullock et al. [8]. 
4.2. Participants and Data Collection 
Patients (18 years or older) under the care of all eight of the hospital’s internal medical teams 
were observed in both study phases. Inpatient medication order forms, the Discharge Medication 
Record (DMR), and medical records were used to collect data before the PTWR and on hospital 
discharge. One experienced pharmacist observed discussions related to individual patients for both 
periods using a structured form to collect patient and medication details communicated. 
All medication-related communication was recorded. Any two-way discussion between medical 
staff or the pharmacist as to whether a treatment modification was described. 
The above briefly summarizes the comparator and intervention observation study described in 
an earlier publication by Bullock et al. [5]. Below is a description of the risk assessment of medication 
recommendations and their impact. 
4.3. Risk Scoring of medication-related recommendations  
A panel of two senior pharmacists and a senior medical officer (an advanced trainee clinical 
pharmacology registrar), all blinded to the arm of the study, completed the risk scoring of all 
medication-related communication for the comparator and intervention cohorts for both:  
(1) Medication-related recommendations that occurred on the PTWR, and; 
(2) Ward-based clinical pharmacist recommendations recorded on the MAP. 
To complete the risk scoring, each episode of medication communication was discussed by the 
panel, along with relevant patient clinical information until a consensus was reached. 
Risk scoring was completed using the PRIME risk matrix (see Appendix A, Table A1) to describe 
the probability of an adverse outcome occurring had a recommendation not been enacted, using a 5-
point scale (see Appendix A, Table A2) from rarely (may occur in exceptional circumstances) to 
almost certain (is expected to occur frequently). As well, the consequence of that event using a 5-point 
scale (see Appendix A, Table A2) of negligible (where no injury or harm would be caused) to 
catastrophic (with the likely consequence of death) was estimated. Following this, the probability and 
consequence were used to determine an overall risk score categorized into five levels of low, medium, 
high, very high, or extreme, which then we grouped as “low and medium”, “high”, or “very high 
and extreme”.  
4.4. Enactment of Medication-related recommendations 
For all medication-related recommendation on the PTWR and the ward, proposed treatment 
modifications were noted as was whether they were able to be actioned (e.g., clear, measurable 
modifications were suggested) and if they were actioned at any time during the patients stay (the 
proposed change was recorded on the patients inpatient medication order form/s, DMR, and/or 
documented in the patients’ medical record). 
4.5. Outcome measures 
The difference between the comparator and intervention groups were compared for: 
• The “low and medium”, “high”, and “very high and extreme” risk scores,  
• The proportion of recommendations that were actioned. 
These comparisons were carried out for both the medication-related recommendations that 
occurred on the PTWR with and without a pharmacist and the ward-based recommendations made 
by pharmacists subsequent to PTWR. 
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4.6. Data analysis  
R commander version 3.2.4 (2016-03-10) was used for data analysis. Patient demographics and 
other continuous data are presented as mean +/- standard deviation (or median and inter quartile 
range where appropriate). Chi-squared tests were used to compare differences in proportions. T-tests 
were used to compare differences in means where data were normally distributed. Categorical and 
binary data have been expressed as counts and percentages of the total number of possible outcomes. 
Statistical significance was achieved if p < 0.05. 
5. Results 
5.1. The clinical significance (Risk Scoring) of Medication Recommendations on the PTWR  
The panel was able to risk rate 230 of the 249 (92.4%) medication-related discussions in the 
comparator group and 326 of the 352 (92.6%) in the intervention group as well as 170 of the 195 
(87.2%) of the ward pharmacist recommendations documented on the MAP in the comparator group 
and 168 of the 225 (74.7%) in the intervention group. The remainder of the medication 
recommendations were unable to be risk rated due to a lack of documented information and were 
excluded from the following analysis. Examples of the risk scoring of medication-related 
recommendations are shown in Table 1. 
Table 1. Examples of the risk scoring system. 
Overall 
level of 
Risk 
Example Probability Consequence Overall risk 
Low  
Medication access/Substitution - patient did not bring 
own supply of rosuvastatin which is not available at 
hospital. Recommendation made to consider 
withholding during hospital admission or change to 
atorvastatin. 
Unlikely Negligible Low 
Medium  
Medication dosage: Patients prescribed thyroxine dose 
usually 100mcg on Sat-Sun, 50mcg Mon-Fri. Currently 
charted 50mcg daily. Recommendation to review and 
chart as appropriate.  
Possible Minor Medium 
High  
Medication withdrawal: Patient charted for regular 
benzodiazepam. Recommendation made to review 
need on discharge with view of dementia and increased 
risk of falls.  
Possible Moderate High 
Very high  
Medication cessation: Patient charted for atenolol and 
sotalol. However, medication history revealed that 
atenolol was changed to sotalol 2 months prior to 
hospital admission. Recommendation to cease the 
atenolol and continue sotalol alone. 
Almost certain Moderate Very high 
Extreme  
Drug interaction: Patient prescribed enoxaparin and 
warfarin therapy. However, INR has 3.9. 
Recommendation to cease enoxaparin and withhold 
warfarin until INR is within target range. 
Almost certain Major Extreme 
Table 2 details the medication recommendations across comparator (no pharmacist present on 
the PTWR) and intervention groups (Pharmacist present and inputting to the PTWR) according to 
their risk score. This table is presented in two parts: Part 1 is PTWR recommendations for both the 
comparator and intervention groups. Part 2 is the ward pharmacist recommendations, which 
occurred on the inpatient wards: These occurred after the PTWT when the patient was admitted to 
the ward.  
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Table 2. The risk scores and enactment of medication-related medication recommendations on the 
post-take ward round (PTWR) and those made by ward-based pharmacists. 
 
Comparator:  
No pharmacist 
present on PTWR  
 
N = 130 patients 
Intervention: 
Pharmacist present on 
PTWR  
 
N = 130 patients 
P 
Value 
Part 1 — Post-Take Ward Round - medication related recommendations 
Low & medium 
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
90 
(0.69 ± 0.88) 
142 
(1.09 ± 1.15) 
0.002^ 
Proportion actioned  
(number actioned/number able to be actioned) 
55/71 
78% 
112/121 
93% 
0.003* 
High 
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
70 
(0.54 ± 0.80) 
115 
(0.88 ± 0.91) 
0.001^ 
Proportion actioned  
(number actioned/number able to be actioned) 
59/65 
91% 
96/106 
91% 
0.965* 
Very high and extreme 
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
70 
(0.54 ± 0.75) 
69 
(0.53 ± 0.78) 
0.935^ 
Proportion actioned  
(number actioned/number able to be actioned) 
53/60 
88% 
56/58 
97% 
0.093* 
Part 2 — Ward-based – Ward Pharmacist Recommendations documented on Medication Action Plan 
Low & medium 
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
112 
(0.86 ± 1.39) 
98 
(0.75 ± 1.23) 
0.509^ 
Proportion actioned  
(number actioned/number able to be actioned) 
82/111 
74% 
64/94 
68% 
0.361* 
High    
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
48 
(0.37 ± 0.64) 
49 
(0.38 ± 0.66) 
0.924^ 
Proportion actioned  
(number actioned/number able to be actioned) 
29/46 
63% 
30/46 
65% 
0.828* 
Very high and extreme    
Number of medication related 
recommendations (mean number per patient ± 
standard deviation) 
13 
(0.10 ± 0.3) 
32 
(0.25 ± 0.51) 
0.006^ 
Proportion actioned  
(number actioned/number able to be actioned) 
9/13 
69% 
22/28 
79% 
0.517*  
Statistical tests: ^ - Welch Two sample t-test, * - Chi-squared 
5.2. Number of medication-related reommendations  
There was a significant increase in the number of PTWR medication-related recommendations 
(comparator 249, baseline 352, P < 0.001) with the presence of a PTWR pharmacist, which was due to 
a significant increase in the number of “low and medium” and “high” risk medication-related 
recommendations , and a similar number of those rated as “very high and extreme” risk. 
By contrast, there was no change in the total number of ward pharmacist recommendations in 
patients seen when a PTWR pharmacist was present (comparator 195, intervention 225, P = 0.22). 
When comparing those able to be risk rated however, more of their recommendations had a “very high and extreme” risk score—32 compared with 13 in the comparator group. 
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5.3. Proportion of medication-related recommendations that were actioned 
Overall, there were significantly more of the actionable PTWR medication-related 
recommendations actioned in the intervention group where there was a pharmacist present on the 
PTWR (comparator 167 of 216 (77%), intervention 264 of 285(86%), P = 0.004). There was a significant 
increase in the proportion of medication-related PTWR recommendations actioned that were rated 
as “low and medium” risk and no significant changes in the other two risk groups.  
Overall, there were a similar number of ward pharmacist recommendations actioned for both 
groups (comparator 120 of 170 (71%), intervention group 116 of 168 (69%), P = 0.76). The proportion 
of ward pharmacist recommendations recorded on the MAP that were actioned across all levels of 
risk score remained similar across risk groups. 
5.4. Proportion actioned depending on setting  
Overall, 85.2% (167/196) of the PTWR medication-related recommendations were actioned in the 
comparator group without any pharmacy input and 93.7% (264/285) in the intervention group. This 
was significantly greater than the proportion of those recommendations actioned by the ward 
pharmacist regardless of if a pharmacist was present on the PTWRD, with 70.6% (120/170) actioned 
in the comparator group and 69% (116/168) in the intervention group. 
6. Discussion 
This paper assigns a panel derived risk score to medication-related communication on the 
PTWR, with and without a pharmacist input and the subsequent recommendations made by the 
ward-based pharmacist (as documented on the MAP); as a measure of the significance of the 
contribution made. This serves to provide previously unreported information on the risk scoring of 
medication communication in these specific settings and explores how those scores are influenced by 
the addition of a PTWR pharmacist. This can assist with prioritizing the role of clinical pharmacists.  
In the earlier publication by Bullock et al. [5] describing medication appropriateness outcomes 
for the same study groups being investigated in this paper, each medication prescribed on the PTWR 
was rated as “high risk” or “not high risk” according to the Australian Safety & Quality Council’s 
APINCH classification system [9]. Although this system of risk assignment is useful and simple to 
implement, a better way to determine the clinical significance of each medication discussion and the 
recommendations made by the pharmacist on the PTWR and the ward-based pharmacist should 
include patient factors such as diagnosis, past medical history, comorbidities, as well as drug-related 
factors including other medication, rather than the actual medication class discussed. The results of 
this study highlight that although there is benefit in prioritizing medication review based on a 
dichotomized categorization system such as APINCH, pharmacists should consider an assessment 
of the probability and potential consequence of addressing the potential or actual DRP as a result of 
each medication in the context of the individual patient.  
Overall, as expected, the presence of a pharmacist on the PTWR resulted in significantly greater 
number of medication-related issues being identified and discussed with medical staff. In particular, 
there were more low, medium, and high risk medication-related recommendations and a similar 
number of recommendations rated as “very high and extreme” risk; there was a non-significantly greater proportion actioned. Additionally, there was a higher proportion of medication 
recommendations actioned in those scored as low and medium risk in the intervention group.  
The reason for this result may be that the presence of the pharmacist, in collaboration with the 
senior medical officers on the ward round, stimulated a focus on the patient’s medication and 
highlighted the importance of low, medium, and high risk interventions to patients’ overall 
medication appropriateness and ensured a greater proportion were actioned by the team during the 
patients stay.  
There was a similar overall number of ward pharmacist recommendations between comparator 
and intervention groups, however a significant increase was noted in those recommendations of very 
high and extreme risk between in the intervention group. These results suggest that the PTWR 
Pharmacy 2020, 8, 23 7 of 9 
 
pharmacist may have an impact over and above what is achieved while on the PTWR, by, enabling 
the ward pharmacist to prioritise more high value interventions. These results combined, may help 
explain the improvements in medication appropriateness shown in the results previously published 
for these study groups [5]. 
Despite the improvement between comparator and intervention groups, there were a number of 
recommendations and recommendations not actioned in both study groups. This highlights an 
opportunity for follow up of the recommendations made on both the PTWR and ward, with a priority 
made to follow up on those recommendations of higher clinical significance. A verbal and written 
handover (for example, via the MAP) to the ward pharmacist and team to ensure follow up is 
essential, which was not mandated in the model of care investigated in this study. The same 
pharmacist fulfilling both PTWR and ward roles may be an alternative model to enable follow 
through on the identified issues however comes with greater demand on staffing and skill mix within 
a hospital pharmacy department. 
This study did not investigate the cost or cost savings of the intervention. This paper, along with 
the earlier publication by Bullock et al., provides further evidence of improved medication 
communication and appropriateness with such an intervention. This evidence calls for further 
economic evaluation to assess whether a PTWR pharmacist service is cost-effective and possibly cost 
saving to the health system [5]. To provide a grounding for future work in this area, Bullock et al. 
recently published a systematic review of the costs and cost-effectiveness of clinical pharmacists on 
hospital ward rounds, which found seven studies of a clinical pharmacist’s inclusion on hospital 
ward rounds; none were deemed to be a full economic evaluation [10]. 
Many pharmacy services prioritise services to inpatient ward-based review over pharmacist 
attendance on ward rounds to ensure completion of key medication management interventions that 
are mandated in National safety and Quality standards such as best practice medication history, 
medication reconciliation on admission, and discharge education and reconciliation in order to 
ensure continuity of quality use of medicines and enhanced patient care [11].This study illustrates a 
higher proportion of recommendations that were actioned on the PTWR as opposed to the ward-
based service alone. It is worth noting that, as recommended by previous research in this area [12], the PTWR pharmacists in this study had well-developed clinical knowledge, communication, and 
interpersonal skills and were able to actively engage with the senior medical decision makers on the 
ward round as opposed to the more junior ward-based pharmacists working with the predominantly 
junior medical staff.  
6.1. Limitations:  
The most relevant limitation to this paper was that there was no system in place to ensure a 
formal written handover between the PTWR pharmacist and ward pharmacist. Some handover 
occurred through written documentation on the National Inpatient Medication Chart or the 
Medication Action Plan, or verbal handover between pharmacists. However, there was no formal 
handover for the majority of patients. 
As mentioned earlier in the paper, the comparator and intervention observations were not 
carried out at the same time of the year (the comparator phase between April and June 2014, and 
intervention phase between August and October 2014) and therefore other changes within the 
hospital such as experience of junior medical and pharmacy staff may have impacted outcomes. The 
observation periods, however, were chosen to minimize this limitation. In addition, the lead 
researcher was not completely independent. Observation bias was minimized by having the same 
observer recording data for both the comparator and intervention groups using a standardized data 
collection method and tool.  
There was some duplication of recommendations on the PTWR and by the ward-based 
pharmacists. These recommendations have not been excluded as the nature and extent of the 
duplication differs greatly and, hence, including but stating the duplicated numbers was the most 
appropriate action. The limitations for this comparator and intervention study are described in more 
detail in the earlier publication by Bullock et al [5]. 
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7. Conclusion 
The inclusion of a pharmacist on the PTWR is associated with more medication-related 
recommendations than with the medical team alone, with a greater proportion rated as “low and 
medium” and “high” and a higher proportion leading to action in those recommendations scored as 
“low and medium”. In addition, ward-based pharmacists seeing patients after a pharmacist attended 
PTWR made more recommendations of “very high and extreme” risk medication than when the 
PTWR did not include a pharmacist. Where resources allow the addition of pharmacists to the PTWR 
in addition to prioritized ward-based services, this is likely to improve medication appropriateness 
over and above that of existing pharmacy services.  
Author Contributions: Conceptualization, BB, IC, CM, PD.; methodology, BB, IC, PD, CM; software, 
BB, PD; validation, BB, PD, formal analysis, BB, IC, PD; investigation, BB; writing—original draft 
preparation, BB.; writing—review and editing, IC, PD, JW, CM; supervision, IC, PD, JW, CM.; 
funding acquisition, BB, IC. All authors have read and agreed to the published version of the 
manuscript. 
Funding: This research was partly funded by Royal Brisbane and Women’s Hospital Foundation. 
Acknowledgements 
• Dr Andrew Finch 
• All medical officers, patients, and staff who participated in this study 
• Department of Internal Medicine, Royal Brisbane & Women’s Hospital 
• Royal Brisbane and Women’s Hospital Foundation 
• Professor Jennifer A. Whitty is supported by the National Institute for Health Research 
(NIHR) Applied Research Collaboration (ARC) East of England. The views expressed are those of 
the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social 
Care. 
Conflicts of Interest: The authors declare no conflict of interest. 
Appendix 
Table A1. Risk rating according to PRIME™ risk matrix: Probability x Consequence = Risk. 
 Consequence 
Probability Negligible Minor Moderate Major Catastrophic 
Rare Low Low Low Medium High 
Unlikely Low Medium Medium High Very High 
Possible Low Medium High Very High Very High 
Likely Medium High Very High Very High Extreme 
Almost 
Certain Medium Very High Very High Extreme Extreme 
Table A2: Description of Probability and Consequence Ratings. 
Probability Consequence - Adverse Clinical Incident 
Rare May occur in exceptional 
circumstances 
Negligible 
No injury or harm caused, 
minor adjustment to operational 
routine 
Unlikely 
Might occur at some time (not to be 
expected) 
Minor 
Minimal harm caused, minor 
interruption to routine 
Possible 
Could occur at least once (capable of 
happening/foreseeable) 
Moderate 
Loss of function, major harm 
caused 
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Likely 
Is expected to occur occasionally (to 
be expected) Major Loss of life 
Almost 
Certain 
Is expected to occur frequently (in 
most circumstances Catastrophic Multiple deaths 
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